ARCHIMED to acquire a majority stake in Arkstone.

ARCHIMED, a private equity firm, agreed to acquire a majority stake in Arkstone, a provider of AI-powered clinical decision support solutions. Financial terms were not disclosed. "Arkstone's OneChoice Report is redefining infectious disease management. Our partnership will enable Arkstone to reach more markets, accelerate product innovation, and ultimately save lives by reducing the misuse of antibiotics. This deal offers an additional dimension, as Clinical Decision Support software (CDS) and infectious disease are at the crossroads of hot subsectors of our Healthcare IT and Diagnostics franchises," Igor Petricca, ARCHIMED Partner.